Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.33 |
| ▸ | PDXK | O00764 | 1/20 | 0.33 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.33 |
| ▸ | STK16 | O75716 | 1/20 | 0.33 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494141 | 0.82 | PIK3CG (0.33) | PIK3CGMAPT | |
| SCHEMBL2492490 | 0.79 | MAPT (0.35) | PIK3CGCASP1PIK3CDPIK3C2BPDXK | |
| SCHEMBL24726396 | 0.79 | PIK3CG (0.49) | PIK3CGCASP1PIK3CDPIK3C2BPDXK | |
| SCHEMBL30570888 | 0.79 | MAPT (0.35) | PIK3CGCASP1PIK3CDPIK3C2BPDXK | |
| SCHEMBL5027008 | 0.73 | CYP1A2 (0.47) | — | |
| Isoxanthopterin SCHEMBL4389432 | 0.72 | PIK3CG (0.46) | PIK3CGCASP1PIK3CDPIK3C2BPDXK | |
| SCHEMBL24629319 | 0.72 | PIK3CG (0.42) | PIK3CGPIK3CAPIK3CBADORA2ADHFR | |
| Xanthopterin SCHEMBL906220 | 0.72 | PIK3CG (0.46) | PIK3CGPIK3CAPIK3CBADORA2ADHFR | |
| SCHEMBL12954844 | 0.71 | PIK3CG (0.70) | PIK3CGCASP1PIK3CDPIK3C2BPDXK | |
| Pterine SCHEMBL4364328 | 0.70 | ADORA2A (0.63) | PIK3CGCASP1PIK3CDPIK3C2BPDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024084421-A1 | TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2 | QRGENETICS LTD. (IL) | 2024-04-25 | — | — | WO | claimed |
| WO-2011138142-A1 | COMPOSITIONS AND USE OF SULFASALAZINE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-11-10 | — | — | WO | claimed |
| US-20110207753-A1 | METHODS FOR TREATING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2011-08-25 | — | — | US | claimed |
| US-20110009351-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therepeutics Inc. | 2011-01-13 | — | — | US | claimed |
| EP-2152276-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | Traffick Therapeutics Inc. (CA) | 2010-02-17 | — | — | EP | claimed |
| EP-2001877-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | Bioniqs Limited (GB) | 2008-12-17 | — | — | EP | claimed |
| WO-2008138123-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | THOMAS DAVID Y (CA) | 2008-11-20 | — | — | WO | claimed |
| WO-2007110637-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | BIONIQS LIMITED (GB) | 2007-10-04 | — | — | WO | claimed |
| EP-1696877-A2 | METHODS FOR TREATING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2006-09-06 | — | — | EP | claimed |
| US-20050197341-A1 | Methods for treating pain | GENERAL HOSPITAL CORPORATION, THE | 2005-09-08 | — | — | US | claimed |
| WO-2005048926-A2 | METHODS FOR TREATING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| JP-4208210-A | — | — | None | — | — | JP | disclosed |
| US-20250255873-A1 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | QRGENETICS LTD. (IL) | 2025-08-14 | — | — | US | disclosed |
| WO-2024084421-A1 | TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2 | QRGENETICS LTD. (IL) | 2024-04-25 | — | — | WO | disclosed |
| US-20130210826-A1 | METHODS FOR TREATING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2013-08-15 | — | — | US | disclosed |
| WO-1996027572-A1 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA ARTHUR M (US) | 1996-09-12 | — | — | WO | disclosed |
| US-5173389-A | Polyhydroxy material reacted with 1,2-naphthoquinonediazide-4 or 5-sulfonyl chloride; novolak binder | FUJI PHOTO FILM CO., LTD. (JP) | 1992-12-22 | — | — | US | disclosed |
| JP-H04208210-A | SKIN COSMETIC | NONOGAWA SHOJI KK | 1992-07-29 | — | — | JP | disclosed |
| EP-0395049-A1 | Positive-working photoresist composition | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0148787-A2 | Positive type photosensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210826-A1 | METHODS FOR TREATING PAIN | SPR, QDPR, SHMT1 | PIK3CG 4261/4885CASP1 2025/4885PIK3CD 4423/4885 |
| US-20250255873-A1 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | ACTR2, ACTB, ACTR3 | PIK3CG 3575/4885CASP1 4644/4885PIK3CD 3532/4885 |
| US-20110009351-A1 | SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS | CLINT1, SLC47A2, GOLT1B | PIK3CG 3981/4885CASP1 4745/4885PIK3CD 3314/4885 |
| US-20110207753-A1 | METHODS FOR TREATING PAIN | SPR, QDPR, SHMT1 | PIK3CG 4394/4885CASP1 2771/4885PIK3CD 4359/4885 |
| US-20050197341-A1 | Methods for treating pain | SPR, QDPR, SHMT1 | PIK3CG 4394/4885CASP1 2771/4885PIK3CD 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.